MSF deal to bring generic next-gen HCV therapies to developing world

31 October 2017

Humanitarian aid group Médecins Sans Frontières (MSF) says it has secured a supply of generic hepatitis C medicines at $1.40 per day, or $120 per 12-week treatment course for the two key medicines sofosbuvir and daclatasvir.

The price significantly undercuts the $1,400 to $1,800 per 12-week treatment MSF had agreed to pay US biotech giant Gilead Sciences (Nasdaq: GILD) and New York’s Bristol-Myers Squibb (NYSE: BMS) in 2015.

Daclatasvir is marketed as Daklinza by Bristol-Myers and sofosbuvir is sold under the brand name Sovaldi by Gilead.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK